Navigation Links
Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing
Date:9/29/2009

IPSWICH, Mass., Sept. 29 /PRNewswire/ -- Dr. John McPherson, Platform Leader, Cancer Genomics and High-Throughput Screening, and Dr. Kamran Shazand, Project Manager, of the Ontario Institute for Cancer Research (OICR) led a team of scientists who have completed a thorough evaluation of the NEBNext(TM) DNA Sample Prep Reagents for use with OICR's Illumina® Genome Analyzer II. Dr. McPherson said of the evaluation, "We are constantly striving for the best quality sequencing results at a price that does not restrict our throughput needs and NEB's new reagents meet this need well."

(Logo: http://www.newscom.com/cgi-bin/prnh/20090921/NE79207LOGO-b )

"We are extremely pleased that OICR, as a world leading genome center, has determined that our reagents meet their high standards," stated Dr. Peter Nathan, Director of Global Business Development at New England Biolabs.

NEBNext(TM) DNA Sample Prep Reagent Sets contain enzymes and buffers that are ideally suited for sample preparation for next generation sequencing, and for preparation of expression libraries. Reagents are available for each step of the library construction workflow, including end repair, dA-tailing, adapter ligation and amplification. These sets are highly cost effective and each of the components must pass rigorous quality control and validation, including independent third-party evaluation on the appropriate NGS platform.

About New England Biolabs (NEB)

Established in the mid 1970's, New England Biolabs, Inc. leads the industry in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genome research. NEB continues to expand its product offerings into areas related to PCR, cloning, expression and purification, and is focusing on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit (http://www.neb.com)

About Ontario Institute for Cancer Research (OICR)

The Ontario Institute for Cancer Research is a new innovative cancer research centre, moving Ontario to the forefront of discovery and innovation. It is dedicated to research in prevention, early detection, diagnosis and treatment of cancer. OICR is a not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation. For more information about OICR, visit (http://www.oicr.on.ca)

SOURCE New England Biolabs


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nanocopoeia Licenses New Polymer-Based Biomaterials Platform From the University of Western Ontario
2. Sparking Growth In Ontarios Biopharmaceutical Industry
3. Senate President Therese Murray, Massachusetts Life Sciences Center, and Howard Hughes Medical Institute Join Marine Biological Laboratory (MBL) for Loeb Laboratory Groundbreaking Ceremony
4. CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc.
5. HUYA Bioscience Establishes First-Look Agreement With Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH)
6. SRA International Wins $16 Million Contract from Cancer Prevention and Research Institute of Texas
7. Pacific Health Research Institute Awarded $2.8 Million in Research Funding
8. Pacific Health Research Institute Awarded $2.8 Million in Research Funding
9. Bayer CropScience Announces Investment of $25 Million for Institute Site
10. Korea Institute of Toxicology Implementing Xybion's Pristima™
11. K-States Biosecurity Research Institute Gives Researchers the Tools Needed to Study Diseases That Cost Pig Producers Hundreds of Millions of Dollars Each Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Eutilex Co. Ltd. today announced that ... Series A financing. This financing round included participation from ... SNU Bio Angel. This new funding brings the total ... $27.7M) since its founding in 2015. ... and commercialization of its immuno-oncology programs, expand its R&D ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new ... the setting of previously treated, advanced pancreatic cancer, liquid biopsies are not yet ... population and timing of blood sampling may improve the value of a blood-based ...
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
(Date:12/7/2016)... 7, 2016  Vyriad Inc. announced today the appointment ... Board of Directors. "We are delighted to ... business and develop our oncolytic viruses as the next ... Stephen Russell , MD, PhD, CEO of Vyriad. "Al ... vision and passion for making a difference for cancer ...
Breaking Biology Technology:
(Date:11/24/2016)... Nov. 23, 2016 Cercacor today introduced Ember ... their trainers non-invasively measure hemoglobin, Oxygen Content, ... and Respiration Rate in approximately 30 seconds. Smaller than ... and immediate access to key data about their bodies ... training regimen. Hemoglobin carries oxygen to ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):